Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabixir
- Development stage
- Preclinical
01
Overview
Cannabixir is an EU-GMP certified Cannabis sativa L. product, specifically "Medium Flos". It is being investigated for its therapeutic potential in Alzheimer's disease due to its role as a cannabinoid receptor ligand. Preclinical studies in APP/PS1 mice have shown that chronic intermittent exposure to Cannabixir can reduce anxiety-like behavior, partially reverse cognitive deficits, decrease Aβ plaque deposits, reduce cerebral glucose metabolism, and modulate the expression of mTOR and CB2 receptors, as well as M1 mAChR. These findings highlight its impact on the expanded endocannabinoid system and its potential neuroprotective and cognitive-enhancing effects.
- Brand names
- Cannabixir Medium Flos
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on Cannabixir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cannabixir.